Nippon Kayaku Kabushiki Kaisha

Kan Saiga

Yuki Kobayashi

Toshihiko Hayashi

Akira Masuda

Makoto Morita

Keiichirou Yamamoto

Toshio Tanabe

Arihiro Tomura

Kyuichi Nemoto

Hisako Takagi

Takamichi Sato

Isamu Koyama

Yoshitaka Satoh

Takako Mae

Kana Mizunuma

Yuji Akiyama

Junpei Konno

Eriko Toyoda

Tadaki Yasumura

Hidemitsu Sugihara

Atsuko Isoda

Nao Yoneki

Kazuhiro Tokunaka

Yasutada Imamura

Akihiro Sekiguchi

Eriko; Toyoda

An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.

Polymer derivative of macrolide immunosuppressant

A monoclonal antibody, wherein the monoclonal antibody specifically binds to a single-chain type IV collagen polypeptide, and wherein the monoclonal antibody is obtained by a hybridoma line of Anti NK-Antigen monoclonal antibody #141 having Accession No: FERM BP-11300.

Anti-single-chain type IV collagen polypeptide antibody, pharmaceutical drug, diagnostic, preventive, or therapeutic drug for tumour containing the antibody

Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow. 

[1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof

A method for detecting the onset of chronic rejection at an early stage after organ transplantation, characterized by assaying nitrogen trioxide (NO,), matrix metalloproteinase (MMP)-2 or the precursor thereof in body fluids drawn out of body.

Method for examining chronic rejection reactions following organ transplantation and method for determining urine components

Growing community of inventors

Tokyo, Japan

Kan Saiga